SCHEMBL712204

SCHEMBL712204

O=S(=O)(Nc1nccs1)c1ccc(Br)cc1OC(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 3/20 0.59
SCN9A Q15858 7/20 0.50
SCN3A Q9NY46 3/20 0.50
SCN1A P35498 3/20 0.50
SCN5A Q14524 3/20 0.50
SCN8A Q9UQD0 3/20 0.50
KCNH2 Q12809 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN10A Q9Y5Y9 1/20 0.50
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.47
ESR2 Q92731 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PPARG P37231 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
KMT2A Q03164 1/20 0.46
ALOX12 P18054 1/20 0.44
HSD17B1 P14061 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712317 0.80 SCN9A (0.60) SCN9ASCN3ASCN1ASCN5ASCN8A
SCHEMBL15212145 0.77 PKM (0.64) ALPLSCN9AUSP2MAPTESR2
SCHEMBL714370 0.77 MEN1 (0.44) SCN9ASCN3ASCN1ASCN5ASCN8A
SCHEMBL713884 0.75 SCN9A (0.52) SCN9ASCN1ASCN5ASCN8AUSP2
SCHEMBL4173014 0.75 SCN9A (0.66) SCN9ASCN3ASCN1ASCN5ASCN8A
SCHEMBL3018907 0.74 ALPL (0.58) ALPLPPARGHSD17B1HSD17B2ADRA2A
SCHEMBL22252121 0.73 ALPL (0.61) ALPLPPARGHSD17B1HSD17B2ADRA2A
SCHEMBL3019244 0.73 ALPL (0.57) ALPLPPARGHSD17B1HSD17B2ADRA2A
SCHEMBL26530281 0.73 SCN3A (0.71) SCN9ASCN3ASCN5AMEN1ALDH1A1
SCHEMBL709771 0.72 SCN9A (0.52) SCN9ASCN3ASCN1ASCN5ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALPL 4043/4885SCN9A 17/4885SCN3A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.